Barclays
AGRX

Barclays’s Agile Therapeutics AGRX Stock Holding History

Barclays’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6
Closed -$11K – 4887
2021
Q3 		$11K Buy
6
+2
+50% +$4.53K ﹤0.01% 4509
2021
Q2 		$10K Sell
4
-24
-86% -$79.1K ﹤0.01% 4660
2021
Q1 		$118K Buy
28
+17
+155% +$91.9K ﹤0.01% 3936
2020
Q4 		$63K Buy
+11
New +$64.7K ﹤0.01% 4320
2018
Q2 		– Sell
-12
Closed -$64K – 7404
2018
Q1 		$64K Sell
12
-31
-72% -$205K ﹤0.01% 5705
2017
Q4 		$233K Buy
43
+33
+330% +$307K ﹤0.01% 4567
2017
Q3 		$93K Sell
10
-4
-29% -$30.7K ﹤0.01% 4982
2017
Q2 		$107K Buy
14
+5
+56% +$34.6K ﹤0.01% 4851
2017
Q1 		$57K Buy
+9
New +$45.2K ﹤0.01% 5267
2016
Q4 		– Hold
0
– – – 6286
2016
Q3 		– Sell
-2
Closed -$28.5K – 6483
2016
Q2 		$26K Buy
+2
New +$27.4K ﹤0.01% 5169
2015
Q4 		– Hold
0
– – – 6748
2015
Q3 		– Hold
0
– – – 7139
2015
Q2 		– Hold
0
– – – 6843

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's AGRX Position: Q4 2021 in Review

Barclays sold out of Agile Therapeutics (AGRX) in Q4 2021, closing a stake of 6 shares — an estimated $11K sold.

Barclays first reported a position in AGRX in Q2 2016 and held it in 10 quarters. The position peaked at $233K in Q4 2017. 45 funds tracked by Wall St. Rank hold AGRX as of Q4 2021.

  • Barclays reported no remaining Agile Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Barclays sold 6 Agile Therapeutics shares in Q4 2021, an estimated $11K.
  • Barclays first reported a position in Agile Therapeutics in Q2 2016 and held it in 10 quarters.
  • Barclays's Agile Therapeutics position peaked at $233K in Q4 2017.
  • 45 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.